Vandermeers A, Vandenborre S, Hou X, de Neef P, Robberecht P, Vandermeers-Piret M C, Christophe J
Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Belgium.
Eur J Biochem. 1992 Sep 15;208(3):815-9. doi: 10.1111/j.1432-1033.1992.tb17252.x.
N-terminally shortened analogs of the 27-amino-acid and 38-amino-acid forms of the pituitary-adenylate-cyclase-activating neuropeptide, PACAP(1-27) and PACAP(1-38), were synthesized by a solid-phase method. Systematic deletion of the first 13 amino acids of both PACAP was tested by evaluating their ability to occupy the specific and selective PACAP receptor of human neuroblastoma NB-OK-1 cell membranes and to stimulate adenylate cyclase or, when inactive per se, to inhibit PACAP-stimulated adenylate cyclase activity. For each peptide, the Kact (concentration required for half-maximal adenylate cyclase activation) or Ki [concentration required to shift the dose/response curve of PACAP(1-27) twofold to the right] was in good agreement with the corresponding IC50 [concentration inhibiting 50% of 125I-[AcHis1]PACAP(1-27) binding to membranes], suggesting interaction with the same homogeneous class of adenylate cyclase-coupled receptors. The deletion of the two first amino acids (His1 and Ser2) sufficed to decrease the affinity for receptors and to suppress the capacity to activate adenylate cyclase. The shorter fragments 3-27 and 3-38, 4-27 and 4-38, 5-27 and 5-38, 6-27 and 6-38, 7-27 and 7-38, 8-27 and 8-38, and 9-27 and 9-38 were all competitive antagonists of PACAP(1-27)-stimulated activity with the N-terminally shortened PACAP(1-38) derivatives being 4-30-fold more potent than the equivalent PACAP(1-27) derivatives. In this group PACAP(6-38) was the most potent antagonist (Ki 1.5 nM). Surprisingly, the N-terminally shorter fragments 10-27 and 10-38, 11-27 and 11-38, 12-27 and 12-38, 13-27 and 13-38, and 14-27 and 14-38 were again able to stimulate adenylate cyclase, the smallest fragments, PACAP(14-27) and PACAP(14-38), being the most potent and efficient (Kact 2 microM and 0.1 microM, respectively). In this group of agonists, PACAP(1-38) derivatives deleted at the N-terminus were also more potent than the equivalent PACAP(1-27) derivatives.
采用固相法合成了垂体腺苷酸环化酶激活神经肽(PACAP)27个氨基酸和38个氨基酸形式的N端截短类似物,即PACAP(1 - 27)和PACAP(1 - 38)。通过评估它们占据人神经母细胞瘤NB - OK - 1细胞膜特异性和选择性PACAP受体的能力以及刺激腺苷酸环化酶的能力,或者在自身无活性时抑制PACAP刺激的腺苷酸环化酶活性的能力,对PACAP的前13个氨基酸进行了系统缺失测试。对于每种肽,Kact(腺苷酸环化酶激活至最大活性一半所需的浓度)或Ki [使PACAP(1 - 27)的剂量/反应曲线右移两倍所需的浓度]与相应的IC50 [抑制50%的125I - [AcHis1]PACAP(1 - 27)与膜结合的浓度]高度一致,表明与同一类均一的腺苷酸环化酶偶联受体相互作用。缺失前两个氨基酸(His1和Ser2)足以降低对受体的亲和力并抑制激活腺苷酸环化酶的能力。较短的片段3 - 27和3 - 38、4 - 27和4 -
38、5 - 27和5 - 38、